PMID- 26245475
OWN - NLM
STAT- MEDLINE
DCOM- 20160803
LR  - 20190911
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 16
IP  - 11
DP  - 2015
TI  - The Current Indications and the Benefits of Combining a beta3-Agonist with an 
      Anticholinergic for the Treatment of OAB.
PG  - 1198-206
AB  - Combination therapy with anti-muscarinics (AMs) and beta3 agonists (beta3As) has 
      recently been proposed as a possible treatment for the management of patients 
      with Overactive Bladder (OAB). EVIDENCE ACQUISITION: A National Center for 
      Biotechnology Information PubMed search for relevant articles published between 
      2007 and 2014 was performed by combining the following Patient population, 
      Intervention, Comparison, Outcome (PICO) terms: overactive bladder, 
      antimuscarinics, beta3 agonists, combination therapy, efficacy, tolerability and 
      outcomes. Additional references were obtained from the reference list of 
      full-text manuscripts. Abstracts presented at the annual congresses of the 
      European Association of Urology, American Urology Association and the 
      International Continence Society were included. EVIDENCE SYNTHESIS: The 
      combination therapy, in the management of OAB symptoms, has recently been 
      investigated in animal models and in a phase II randomized clinical trial. 
      Compared with AMs monotherapy, combination treatment improved mean voided volume 
      per micturition, micturition frequency and reduced urgency episodes. No dose 
      related trends in adverse events (AEs) were observed between combination group 
      and monotherapy group. Incidence of constipation was slightly increased in 
      combination therapy group. CONCLUSIONS: Combination therapy seems to be an 
      effective and safe treatment in the management of OAB. However, further 
      cost-effectiveness studies are needed to evaluate the definitive role of this 
      approach for the management of patients with OAB.
FAU - De Nunzio, Cosimo
AU  - De Nunzio C
AD  - Ospedale Sant'Andrea, University "La Sapienza", Roma, Italy. 
      cosimodenunzio@virgilio.it.
FAU - Presicce, Fabrizio
AU  - Presicce F
FAU - Pirozzi, Luisella
AU  - Pirozzi L
FAU - Castellan, Pietro
AU  - Castellan P
FAU - Schips, Luigi
AU  - Schips L
FAU - Cindolo, Luca
AU  - Cindolo L
FAU - Lombardo, Riccardo
AU  - Lombardo R
FAU - Tubaro, Andrea
AU  - Tubaro A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - 0 (Adrenergic beta-3 Receptor Agonists)
RN  - 0 (Cholinergic Antagonists)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Receptors, Adrenergic, beta-3)
SB  - IM
MH  - Adrenergic beta-3 Receptor Agonists/administration & dosage/*therapeutic use
MH  - Cholinergic Antagonists/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Muscarinic Antagonists/administration & dosage/therapeutic use
MH  - Receptors, Adrenergic, beta-3
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy
EDAT- 2015/08/08 06:00
MHDA- 2016/08/04 06:00
CRDT- 2015/08/07 06:00
PHST- 2014/06/20 00:00 [received]
PHST- 2015/02/08 00:00 [revised]
PHST- 2015/08/06 00:00 [accepted]
PHST- 2015/08/07 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2016/08/04 06:00 [medline]
AID - CDT-EPUB-69362 [pii]
AID - 10.2174/1389450116666150806124345 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2015;16(11):1198-206. doi: 10.2174/1389450116666150806124345.